Asia-Pacific Journal of Medicine

| Peer-Reviewed |

Progress in Research of miRNA in Multiple Myeloma

Received: 06 January 2020    Accepted: 15 March 2020    Published: 16 March 2020
Views:       Downloads:

Share This Article

Abstract

Objective: Small interfering RNA (miRNA) is a kind of endogenous small RNA with 20-24 nucleotides in length. It is speculated that miRNA regulates one third of human genes. In this paper, the research status and progress of miRNA in the field of multiple myeloma (MM) were summarized to provide data for the follow-up study, and to seek breakthrough points, methods and demonstration basis. Methods: By inputting key words and so on, literatures were searched in the bibliographic databases of Cnki, PubMed, Google, etc., and read online or downloaded to analyze and summarize. Results: 419 related literatures were successfully retrieved, 57 were intensively read and 17 were cited. Conclusion: Abnormally expressed miRNAs promote the occurrence and development in Multiple Myeloma, and have very important role in diagnosis, prognosis and drug resistances in MM.

Published in Asia-Pacific Journal of Medicine (Volume 3, Issue 1, March 2020)
Page(s) 5-8
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

miRNAs, Multiple Myeloma, Abnormal Expression, Diagnosis, Prognosis, Drug Resistance

References
[1] Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111 (6): 2962–2972.
[2] Palumbo A, Anderson K. Multiple myeloma. N. Engl. J. Med.2011; 364 (11): 1046–1060.
[3] Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 2016; 374 (17): 1621–1634.
[4] Hao M, Zhang L, An G, et al. Bone marrow stromal cells protect myeloma cells form bortezomib induced apoptosis by suppressing mirNA-15a expression, Leuk. Lymphoma 52 (2011) 1787–1794.
[5] Li F, Xu Y, Deng S, et al. MicroRNA-15a/16-1 cluster located at chromosome13q14 is down-regulated but displays different expression pattern andprognostic significance in multiple myeloma, Oncotarget 6 (2015) 38270–38282.
[6] Sun CY, She XM, Qin Y, et al, mir-15a and mir-16 affect the angiogenesis of multiple myeloma by targeting VEGF, Carcinogenesis 34 (2013) 426–435.
[7] Xiong Q, Zhong Q, Zhang J,, et al. Identification of novel mir-21 target proteins in multiple myeloma cells by quantitative proteomics. J Proteome Res. 2012; 11: 2078–90.
[8] Benetatos L, Vartholomatos G. Deregulated microRNAs in multiple myeloma. Cancer. 2012; 118: 878–87.
[9] Y.K. Zhang, H. Wang, Y. Leng, et al. Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1.Biochem Biophys Res Commun, 414 (2011), pp. 233–239.
[10] N. Amodio, M.T. Di Martino, U. Foresta, et al.mir-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.Cell Death Disease, 3 (2012), p. e436.
[11] Chen LJ, Li CM, Zhang R, et al. mir-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. 2011, 309 (1): 62-70.
[12] Kubiczkova L, Kryukov F, Slaby O,et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica, 2014, 99: 511–518.
[13] Yoshizawa S, Ohyashiki JH, Ohyashiki M, et al. Downregulated plasma mir-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J, 2012, 2: e53
[14] Qu X, Zhao M, Wu S,et al. Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma. Med Oncol, 2014, 31: 219.
[15] Munker R, Liu CG, Taccioli C, et al. MicroRNA profiles of drug-resistant myeloma cell lines. Acta Haematol 2010; 123: 201-204.
[16] Zhang L, Pan L, Xiang B, et al.Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. Oncotarget 2016; doi: 10.18632/oncotarget.9021.
[17] Gulla A, Di Martino MT, Gallo Cantafio ME, et al. A 13mer LNA-i-mir-221 Inhibitor Restores Drug Sensitivityin Melphalan-Refractory Multiple Myeloma Cells. ClinCancer Res 2016; 22: 1222-1233.
Author Information
  • Department of Hematology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan, China

  • Department of Hematology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan, China

Cite This Article
  • APA Style

    Fen Yang, Hong Han. (2020). Progress in Research of miRNA in Multiple Myeloma. Asia-Pacific Journal of Medicine, 3(1), 5-8.

    Copy | Download

    ACS Style

    Fen Yang; Hong Han. Progress in Research of miRNA in Multiple Myeloma. Asia-Pac. J. Med. 2020, 3(1), 5-8.

    Copy | Download

    AMA Style

    Fen Yang, Hong Han. Progress in Research of miRNA in Multiple Myeloma. Asia-Pac J Med. 2020;3(1):5-8.

    Copy | Download

  • @article{10045991,
      author = {Fen Yang and Hong Han},
      title = {Progress in Research of miRNA in Multiple Myeloma},
      journal = {Asia-Pacific Journal of Medicine},
      volume = {3},
      number = {1},
      pages = {5-8},
      url = {http://www.sciencepg.com/article/10045991},
      abstract = {Objective: Small interfering RNA (miRNA) is a kind of endogenous small RNA with 20-24 nucleotides in length. It is speculated that miRNA regulates one third of human genes. In this paper, the research status and progress of miRNA in the field of multiple myeloma (MM) were summarized to provide data for the follow-up study, and to seek breakthrough points, methods and demonstration basis. Methods: By inputting key words and so on, literatures were searched in the bibliographic databases of Cnki, PubMed, Google, etc., and read online or downloaded to analyze and summarize. Results: 419 related literatures were successfully retrieved, 57 were intensively read and 17 were cited. Conclusion: Abnormally expressed miRNAs promote the occurrence and development in Multiple Myeloma, and have very important role in diagnosis, prognosis and drug resistances in MM.},
     year = {2020}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Progress in Research of miRNA in Multiple Myeloma
    AU  - Fen Yang
    AU  - Hong Han
    Y1  - 2020/03/16
    PY  - 2020
    T2  - Asia-Pacific Journal of Medicine
    JF  - Asia-Pacific Journal of Medicine
    JO  - Asia-Pacific Journal of Medicine
    SP  - 5
    EP  - 8
    PB  - Science Publishing Group
    UR  - http://www.sciencepg.com/article/10045991
    AB  - Objective: Small interfering RNA (miRNA) is a kind of endogenous small RNA with 20-24 nucleotides in length. It is speculated that miRNA regulates one third of human genes. In this paper, the research status and progress of miRNA in the field of multiple myeloma (MM) were summarized to provide data for the follow-up study, and to seek breakthrough points, methods and demonstration basis. Methods: By inputting key words and so on, literatures were searched in the bibliographic databases of Cnki, PubMed, Google, etc., and read online or downloaded to analyze and summarize. Results: 419 related literatures were successfully retrieved, 57 were intensively read and 17 were cited. Conclusion: Abnormally expressed miRNAs promote the occurrence and development in Multiple Myeloma, and have very important role in diagnosis, prognosis and drug resistances in MM.
    VL  - 3
    IS  - 1
    ER  - 

    Copy | Download

  • Sections